 |
市場調查報告書
商品編碼
1427023
醫藥產業5大成長機會，2024年Top 5 Growth Opportunities for the Pharmaceutical Industry, 2024 |
||||||
技術支援的合作夥伴關係加速了精準腫瘤學、罕見疾病和肥胖症領域的藥物研發和開發
到2024年，生命科學（LS）產業預計將更加關注精準健康。 LS公司將提高基於體學的研究能力，部署人工智慧和生物資訊學，並越來越發現個人化治療方法。製藥公司和技術供應商之間的合作夥伴關係預計將繼續擴大，以支持罕見疾病、肥胖和癌症的藥物研發發現創新。
針對先前無法成藥的目標的可能性將推動核糖核酸（RNA）技術、蛋白質降解（PROTAC）和抗體工程技術的投資和合作。精準腫瘤學是一個重要的重點領域，並透過建立更多的公私夥伴關係來加強。製藥公司、合約研究組織（CRO）、數位療法、診斷公司、真實世界證據（RWE）解決方案供應商、次世代定序（NGS）公司和醫療設備參與者之間的跨產業合作將會增加。 人工智慧的實施將加速藥物發現和藥物再利用、臨床試驗民主化和設計、RWD 分析、製造自動化和供應鏈透明度，為患者、醫療保健提供者和整個製藥行業帶來好處。
目錄
2024年主要成長機會
- 策略要務
- 5 大成長機會
- 成長機會1：利用人工智慧治療罕見疾病藥物的重複利用
- 成長機會2：中東/亞太地區精準腫瘤學規模化的 PPP
- 成長機會3：藥物研發發現與開發的敏捷合作模式
- 成長機會4：利用新興生物技術平台瞄準藥物研發的蛋白質
- 成長機會5：肥胖治療的聯合治療
- 下一步
- 免責聲明
Tech-enabled Partnerships Propelling Drug Discovery and Development in Precision Oncology, Rare Diseases, and Obesity
In 2024, the life science (LS) industry's focus on precision health will intensify. LS companies will augment their omics-based research capabilities and increasingly deploy AI and bioinformatics to discover personalized therapies. Partnerships between pharmaceutical companies and technology vendors will multiply, to support innovation in drug discovery for rare diseases, obesity, and oncology.
The possibility of targeting previously undruggable targets will drive investments and partnerships in ribonucleic acid (RNA) technology, protein degradation (PROTAC), and antibody engineering technologies. Precision oncology is a vital area of focus, reinforced by the establishment of more public-private partnerships. There will be an increase in cross-industry collaboration between pharmaceutical companies, contract research organizations (CROs), digital therapeutics, diagnostic companies, real-world evidence (RWE) solution vendors, next-generation sequencing (NGS) companies, and medical device players. The implementation of artificial intelligence will intensify for accelerated drug discovery and drug repurposing, clinical trial democratization and design, RWD analysis, manufacturing automation, and supply chain transparency, with resulting benefits extending to patients, healthcare providers, and the pharmaceutical industry overall.
Table of Contents
Top Growth Opportunities for 2024
- Strategic Imperatives
- Top 5 Growth Opportunities
- Growth Opportunity 1: AI-enabled Drug Repurposing for Rare Diseases
- Growth Opportunity 2: PPPs for Precision Oncology Scaleup in Middle East and APAC
- Growth Opportunity 3: Agile Partnership Model for Drug Discovery and Development
- Growth Opportunity 4: Targeting Undruggable Proteins with Emerging Biotech Platforms
- Growth Opportunity 5: Combination Therapies for Obesity Management
- Next Steps
- Legal Disclaimer
